Vertex Pharmaceuticals stock was falling sharply Tuesday after the biotech company reported first-quarter earnings that ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.

Fintel reports that on May 6, 2025, Leerink Partners downgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...

Vertex Pharmaceuticals sees brighter prospects despite Q1 misses, with promising launches, pipeline progress, and upgraded ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. Vertex reported Q1 revenue ...

Vertex Pharmaceuticals (VRTX) and Neurocrine Biosciences (NBIX) shares are moving sharply after their respective earnings ...

Vertex Pharmaceuticals reports first-quarter financial results after the market close on Monday. Here's a look at the key highlights from the period.

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported first-quarter profit of $646.3 million. On a per-share basis, the Boston-based company said it had net income of $2.49 ...

but added Regeneron Pharmaceuticals REGN in 2020 and then Vertex Pharmaceuticals VRTX in 2022. The fund also added pharmaceutical giant Merck MRK in April 2023. Those buys helped push its ...

One positive sign was that Vertex raised the lower end of its forecast for full-year 2025 revenue by $100 million. The ...

CEO Reshma Kewalramani highlighted the company’s strong performance in Q1 2025, with $2.77 billion in revenue, representing a 3% year-over-year increase. Growth was driven by expanding patient reach ...